Usefulness of a multiplex immunodot in case of discordant results between automated COVID-19 serological assays
Copyright © 2021 Elsevier B.V. All rights reserved..
BACKGROUND: At present, the only reliable test for COVID-19 diagnosis is RT-qPCR. Serological assays have been widely used to increase the detection sensitivity of infected population. Hereby, we report the performance of a new pan-IgG multiplex Enzyme Immunoassay (immunodot) method for exploration of discrepant SARS-COV-2 serological results.
METHODS: A retrospective study on 38 residual serum samples from recovered COVID-19 subjects with discordant serological results on Roche and Snibe platforms, were reanalyzed on a new semi-automated pan-IgG immunodot Enzyme Immunoassay, namely COVIDOT-TEST, in order to find the source of discrepancies and to evaluate the latter method. All samples were analyzed on the BlueDiver® Instrument and all strips were read by the BlueScan® Scanner using Dr DOT® Software.
RESULTS: Based on our data, subject samples showed specific IgG reactions on ≥ 2 different antigens on immunodot strips. Of these 38 samples, 97.4 % of samples showed specific IgG reaction against S1 + S2 antigens, 89.5 % showed against RBD antigen, 86.8 % against S2 antigen reaction on the COVIDOT-TEST kit. Specific IgG-S1 antigen and IgG-N antigen reactions were detected in 73.7 % and 65.8 % of the samples, respectively.
CONCLUSION: The new semi-automated pan-IgG immunodot Enzyme Immunoassay method appeared to be a reliable assay to confirm suspicious COVID-19 serological screening results.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:292 |
|---|---|
| Enthalten in: |
Journal of virological methods - 292(2021) vom: 15. Juni, Seite 114129 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Soleimani, Reza [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ALPHADIA (S.A./N.V) |
|---|
| Anmerkungen: |
Date Completed 05.05.2021 Date Revised 17.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jviromet.2021.114129 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323023428 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323023428 | ||
| 003 | DE-627 | ||
| 005 | 20231225183259.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jviromet.2021.114129 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1076.xml |
| 035 | |a (DE-627)NLM323023428 | ||
| 035 | |a (NLM)33745966 | ||
| 035 | |a (PII)S0166-0934(21)00068-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Soleimani, Reza |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Usefulness of a multiplex immunodot in case of discordant results between automated COVID-19 serological assays |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.05.2021 | ||
| 500 | |a Date Revised 17.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: At present, the only reliable test for COVID-19 diagnosis is RT-qPCR. Serological assays have been widely used to increase the detection sensitivity of infected population. Hereby, we report the performance of a new pan-IgG multiplex Enzyme Immunoassay (immunodot) method for exploration of discrepant SARS-COV-2 serological results | ||
| 520 | |a METHODS: A retrospective study on 38 residual serum samples from recovered COVID-19 subjects with discordant serological results on Roche and Snibe platforms, were reanalyzed on a new semi-automated pan-IgG immunodot Enzyme Immunoassay, namely COVIDOT-TEST, in order to find the source of discrepancies and to evaluate the latter method. All samples were analyzed on the BlueDiver® Instrument and all strips were read by the BlueScan® Scanner using Dr DOT® Software | ||
| 520 | |a RESULTS: Based on our data, subject samples showed specific IgG reactions on ≥ 2 different antigens on immunodot strips. Of these 38 samples, 97.4 % of samples showed specific IgG reaction against S1 + S2 antigens, 89.5 % showed against RBD antigen, 86.8 % against S2 antigen reaction on the COVIDOT-TEST kit. Specific IgG-S1 antigen and IgG-N antigen reactions were detected in 73.7 % and 65.8 % of the samples, respectively | ||
| 520 | |a CONCLUSION: The new semi-automated pan-IgG immunodot Enzyme Immunoassay method appeared to be a reliable assay to confirm suspicious COVID-19 serological screening results | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ALPHADIA (S.A./N.V) | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Immunoassay | |
| 650 | 4 | |a Immunodot | |
| 650 | 4 | |a Maglumi™ | |
| 650 | 4 | |a Multiplex | |
| 650 | 4 | |a Roche® | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Serology | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Khourssaji, Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Aupaix, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez-Villalobos, Hector |e verfasserin |4 aut | |
| 700 | 1 | |a Scohy, Anaïs |e verfasserin |4 aut | |
| 700 | 1 | |a Kabamba-Mukadi, Benoît |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of virological methods |d 1981 |g 292(2021) vom: 15. Juni, Seite 114129 |w (DE-627)NLM012608386 |x 1879-0984 |7 nnns |
| 773 | 1 | 8 | |g volume:292 |g year:2021 |g day:15 |g month:06 |g pages:114129 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jviromet.2021.114129 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 292 |j 2021 |b 15 |c 06 |h 114129 | ||